In one paragraphArticle in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Daisy HernandezDepartment of Medicine, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA.ORCID 0000-0002-2473-5613 Ashlie BrowningHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA.
Karlena Lara-OteroCancer Genetics and Genomics Clinic, Stanford Medicine Healthcare, Stanford, CA.
Mariana Niell-SwillerCancer Genetics Services, University of California, Los Angeles (UCLA), Los Angeles, CA.
Jacqueline MerschSimmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
Daniella KamaraCancer Genetics Services, University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0000-0003-4972-9292 Amie BlancoHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA.ORCID 0000-0003-3690-0038 Yvonne CardonaDepartment of Medicine, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA.ORCID 0009-0002-0987-3396 Emmeline ChangUSC Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Los Angeles, CA.ORCID 0000-0002-9098-5522 Jacob G ComeauxDepartment of Medicine, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA.ORCID 0000-0002-0944-5079 Julie O CulverDepartment of Medicine, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA.ORCID 0000-0001-8658-3507 James M FordDepartment of Genetics and Department of Medicine, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-2513-7025 Natalia GutierrezDepartment of Medicine, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA.ORCID 0009-0009-7275-6695 Jenny LesterCancer Genetics Services, University of California, Los Angeles (UCLA), Los Angeles, CA.
Beth Y KarlanCancer Genetics Services, University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0000-0002-9451-2933 Jesus ResendizDepartment of Medicine, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA.ORCID 0009-0009-4436-6067 Maria L WeiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA.ORCID 0000-0002-3568-1921 Charité N RickerDepartment of Medicine, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA.ORCID 0000-0002-0620-9345 Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MUT Southwestern Center for Translational MedicineUL1TR003163 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2021 to 2025
$39.3MNCATS NIH HHS UL1 TR003163NCI NIH HHS P30 CA014089
6 · The paper itselfAbstract
purposePathogenic/likely pathogenic variants (P/LPVs) in the
methodsInstitutional clinical databases were queried for the
resultsData on 203 individuals, with qualifying
conclusionIn the largest I49T study to date to our knowledge, MEL was significantly less frequent compared with known
Indexed as
Cyclin-Dependent Kinase Inhibitor p16MelanomaMexican AmericansPancreatic NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPhenotypeCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16
Identifiers
PMID42753217
PMCPMC13600356
What OpenQuestion holds
Textmetadata
Read underepoch 390